Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Gynecol Oncol. 2013 Jul;130(1):121-6. doi: 10.1016/j.ygyno.2013.04.022. Epub 2013 Apr 20.
Lynch syndrome (LS) is a hereditary condition that increases the risk for endometrial and other cancers. Recognizing women at risk for LS based on personal/family history is burdensome and imprecise. Tumor testing using microsatellite instability (MSI) testing and immunohistochemistry (IHC) for mismatch repair protein expression can be an effective strategy for identifying potential LS in patients presenting with colorectal or endometrial cancer. Here we describe our experience implementing a screening program for endometrial cancers.
Endometrial cancers diagnosed ≤50 years or those with suspicious personal history or histopathologic features were screened with MSI/IHC, June 2009-June 2011. Criteria were later (July 2011-July 2012) expanded to patients diagnosed <60 years, or at any age with suspicious features, and finally (after August 2012) universal screening was implemented. Screening techniques began with both MSI and IHC for every tumor, and later converted to IHC for two proteins, and MLH1 promoter methylation analysis when indicated. A genetic counselor contacted patients directly to offer genetic counseling appointments.
Two hundred and forty-five endometrial cancers (average age, 57 years) were screened. Sixty-two patients (25%) had abnormal results, and 42 patients were referred for genetic counseling. Of the 42 patients, 34 underwent genetic counseling, 28 pursued genetic testing, and 11 were diagnosed with LS. When age and pathology criteria were used, 27 eligible cases were overlooked for screening and 3 cases of LS were found only because a clinician requested screening.
Universal screening of endometrial cancers for LS is practical and successfully implemented with collaboration among genetic counselors, gynecologic oncologists, and pathologists.
林奇综合征(LS)是一种遗传性疾病,会增加子宫内膜癌和其他癌症的风险。根据个人/家族史识别有 LS 风险的女性既繁琐又不准确。通过微卫星不稳定性(MSI)检测和错配修复蛋白表达的免疫组织化学(IHC)对肿瘤进行检测,是一种有效策略,可以在出现结直肠癌或子宫内膜癌的患者中识别潜在的 LS。在此,我们描述了实施子宫内膜癌筛查计划的经验。
2009 年 6 月至 2011 年 6 月,对≤50 岁诊断的子宫内膜癌或具有可疑个人史或组织病理学特征的患者进行 MSI/IHC 筛查。随后(2011 年 7 月至 2012 年 7 月),将标准扩大到<60 岁诊断的患者,或任何年龄有可疑特征的患者,最终(2012 年 8 月后)实施了普遍筛查。筛查技术开始时对每个肿瘤进行 MSI 和 IHC 检测,然后转换为对两种蛋白质进行 IHC 检测,以及在需要时进行 MLH1 启动子甲基化分析。遗传咨询师直接联系患者提供遗传咨询预约。
共筛查了 245 例子宫内膜癌(平均年龄 57 岁)。62 例患者(25%)结果异常,42 例患者被转介接受遗传咨询。在 42 例患者中,34 例接受了遗传咨询,28 例接受了基因检测,11 例被诊断为 LS。当使用年龄和病理学标准时,有 27 例符合条件的病例被漏筛,而 3 例 LS 仅因为临床医生要求筛查而被发现。
LS 的子宫内膜癌普遍筛查是可行的,通过遗传咨询师、妇科肿瘤学家和病理学家之间的合作成功实施。